We are monitoring the impact of COVID-19 on Europe Nuclear Imaging Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1545
Share on
Share on

Europe Nuclear Imaging Market Research Report – Segmented By Diagnostic Technologies, Application, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1545
Pages: 133

Europe Nuclear Imaging Market Size (2021 to 2026)

The size of the Europe Nuclear Imaging Market is estimated to be worth USD 4.90 by 2026 and USD 3.22 billion in 2021, growing at a CAGR of 8.48% from 2021 to 2026.

The increased emphasis on personalized medicine has a significant impact on Europe's nuclear imaging technologies market. Rising cancer and cardiac disease incidences and prevalence, increased acceptance of nuclear imaging devices in ambulatory settings, growing geriatric population, untapped emerging markets, increased regulatory approvals, and rising investment in diagnostic imaging centers are key factors driving the European nuclear imaging market. Due to the relevance of nuclear imaging devices in medical imaging procedures, the demand for nuclear imaging has grown over time. The PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) market is being driven by growing awareness of the benefits of nuclear imaging among physicians and clinical researchers and expanding application areas such as cancer and neurological disorders. The market for nuclear imaging in Europe is also growing because of different improvements in radiotracers.

The market for nuclear imaging in Europe is further expected to see many growth opportunities due to the rising demand for data-integrated imaging systems and strong demand. Image processing and reconstruction, computer-assisted medical condition detection, 3D image creation, and the employment of suitable quality control systems are all possible with data integrated imaging systems. In addition, physicians may quickly compare scans with data integration to efficiently monitor disease progression. The growing incidence and death rate and the increasing incidence and mortality rate of cardiac illnesses are driving the expansion of the European Nuclear Imaging market. Furthermore, in the next few years, prospective radioisotopes in the pipeline and cyclotron-based manufacturing are anticipated to provide enormous opportunities for the European Nuclear Imaging market.

The shorter life of radiopharmaceuticals, high costs of nuclear imaging devices, reimbursement regulations, and a lack of nuclear imaging expertise are all predicted to impede the market's expansion in Europe. Continuous reimbursement decreases for diagnostic imaging scans discourage medium- and small-sized healthcare institutions from investing in technologically advanced nuclear imaging modalities. In addition, the market for nuclear imaging in Europe will be challenged by the increased adoption of reconditioned diagnostic systems and hospital budget constraints.

This research report on the European Nuclear Imaging Market has been segmented & sub-segmented into the following categories:

By Product: 

  • Standalone PET Nuclear Imaging
  • Standalone SPECT Nuclear Imaging
  • Hybrid Nuclear Imaging

By Application: 

  • Oncology
  • Cardiology
  • Neurology
  • Others

By End-User: 

  • Hospitals
  • Diagnostic Centers
  • Research Centers

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

In 2020, the German nuclear imaging market accounted for the largest share of the European market, followed by France, Italy, and the United Kingdom. However, this market is projected to witness a high growth rate in developing markets like Switzerland, Poland, Denmark, and Sweden. Companies show a strong interest in enhancing image quality by developing new technologies and creating new devices or novel techniques to achieve images with higher spatial resolution.

The significant rise in the regional market growth can be driven by the rising chronic illness incidence, increased awareness of the advantages of early disease detection, and improved healthcare systems. The European nuclear imaging market is developing because of the increased frequency of cancer and heart diseases and the growing need for image-guided treatments and diagnostics. The market for nuclear imaging in Europe also benefits from the rapid move from standalone to hybrid modalities. Nuclear medicine offers a lot of possibilities in terms of many disease treatments. There is significant evidence that using nuclear imaging methods to diagnose a tumor has a more powerful influence on patient care regarding tumor surveillance and medication response.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the European nuclear imaging market are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Diagnostic Technologies                        

                                5.1.1 Introduction           

                                5.1.2 PET Radioisotopes

                                                5.1.2.1 Rubidium-82

                                                5.1.2.2 Fluorine-18

                                                5.1.2.3 Others

                                5.1.3 SPECT Radioisotopes          

                                                5.1.3.1 Thallium-201

                                                5.1.3.2 Technetium-99m

                                                5.1.3.3 Xenon-133

                                                5.1.3.4 Iodine-123

                                                5.1.3.5 Others

                                5.1.4 Y-o-Y Growth Analysis, By Diagnostic Technologies                

                                5.1.5 Market Attractiveness Analysis, By Diagnostic Technologies              

                                5.1.6 Market Share Analysis, By Diagnostic Technologies               

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 PET             

                                                5.2.2.1 Cardiology

                                                5.2.2.2 Oncology

                                                5.2.2.3 Neurology

                                                5.2.2.4 Others

                                5.2.3 SPECT        

                                                5.2.3.1 Lymphoma

                                                5.2.3.2 Neurology

                                                5.2.3.3 Cardiology

                                                5.2.3.4 Thyroid

                                                5.2.3.5 Others

                                5.2.4 Y-o-Y Growth Analysis, By Application         

                                5.2.5 Market Attractiveness Analysis, By Application        

                                5.2.6 Market Share Analysis, By Application         

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Diagnostic Technologies

                                                6.1.3.3 By Application

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Diagnostic Technologies

                                                6.1.4.3 By Application

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Diagnostic Technologies

                                                6.1.5.3 By Application

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Mallinckrodt plc                        

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Siemens Medical Solutions                  

                8.3 Hitachi Medical Corporation               

                8.4 Medtronic Inc.                          

                8.5 General Electric Co. (healthcare division)                       

                8.6 IBA Group                   

                8.7 Positron Corporation                              

                8.8 Philips Medical Systems                        

                8.9 Naviscan                      

                8.10 Toshiba Medical Systems Corporation                          

                8.11 Carestream Health                

                8.12 Lantheus Medical Imaging Inc.                         

                8.13 Cardinal Health Inc.                              

                8.14 Bayer AG                  

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Nuclear Imaging Market, By Region, From 2021 to 2026 (USD Billion)
  2. Europe Nuclear Imaging Market, By Diagnostic Technologies, From 2021 to 2026 (USD Billion)
  3. Europe PET Radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  5. Europe Rubidium-82 Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Fluorine-18 Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Other PET radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe SPECT Radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  10. Europe Thallium-201 Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Technetium-99m Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Xenon-133 Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Iodine-123 Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Other SPECT radioisotopes Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  16. Europe PET Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  18. Europe Cardiology Market, By Region, From 2021 to 2026 (USD Billion)
  19. Europe Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  21. Europe Other PET applications Market, By Region, From 2021 to 2026 (USD Billion)
  22. Europe SPECT Market, By Region, From 2021 to 2026 (USD Billion)
  23. Europe Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  24. Europe Lymphoma Market, By Region, From 2021 to 2026 (USD Billion)
  25. Europe Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  26. Europe Cardiology Market, By Region, From 2021 to 2026 (USD Billion)
  27. Europe Thyroid Market, By Region, From 2021 to 2026 (USD Billion)
  28. Europe Other SPECT applications Market, By Region, From 2021 to 2026 (USD Billion)
  29. U.K Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  30. U.K Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  31. U.K Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  32. U.K Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  33. U.K Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  34. U.K Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  35. Spain Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  36. Spain Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  37. Spain Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  38. Spain Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  39. Spain Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  40. Spain Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  41. Germany Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  42. Germany Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  43. Germany Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  44. Germany Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  45. Germany Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  46. Germany Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  47. Italy Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  48. Italy Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  49. Italy Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  50. Italy Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  51. Italy Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  52. Italy Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)
  53. France Nuclear Imaging Market, By Diagnostic Technologies , From 2021 to 2026 (USD Billion)
  54. France Nuclear Imaging Market, By PET Radioisotopes, From 2021 to 2026 (USD Billion)
  55. France Nuclear Imaging Market, By SPECT Radioisotopes, From 2021 to 2026 (USD Billion)
  56. France Nuclear Imaging Market, By Application, From 2021 to 2026 (USD Billion)
  57. France Nuclear Imaging Market, By PET, From 2021 to 2026 (USD Billion)
  58. France Nuclear Imaging Market, By SPECT, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample